Development of targeted angiogenic medicine

Area of Science:

• Biomedical research
• Translational medicine
• Angiogenesis research

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for development and disease.
• Vascular endothelial growth factor (VEGF) has been a primary target for anti-angiogenic therapies in cancer and ocular diseases.
• Limitations of VEGF-targeted therapies, including resistance and side effects, necessitate alternative approaches.

Purpose of the Study:

• To review recent advancements in angiogenic medicine.
• To explore novel therapeutic targets beyond VEGF.
• To discuss the implications of angiogenesis modulation in various diseases, including neurodegeneration.

Main Methods:

• Review of current literature on angiogenesis modulation.
• Analysis of emerging therapeutic strategies targeting oxygen-sensitive enzymes and hypoxia-induced transcription factors.
• Evaluation of placental growth factor as a disease-specific angiogenic target.

Main Results:

• VEGF-targeted therapies have shown success but face challenges with resistance and side effects.
• Modulation of prolyl hydroxylase domain proteins and hypoxia-induced transcription factors presents a novel strategy for cancer and ischemic diseases.
• Placental growth factor inhibition effectively reduces cancer growth, while its delivery promotes revascularization in ischemic tissues.

Conclusions:

• Alternative strategies to VEGF are crucial for effective angiogenic medicine.
• Novel targets like placental growth factor offer disease-specific benefits with fewer side effects.
• Angiogenesis modulation holds potential for treating a range of conditions, including neurodegenerative diseases.